CTOs on the Move


 
MyTime is a software company headquartered in San Francisco that provides an all-in-one scheduling, marketing, and point of sale solution for local service businesses like salons, massage therapists, and pet groomers for Enterprises and Franchises as w...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.mytime.com
  • 600, California Street
    San Francisco, CA USA 94108
  • Phone: 888.423.1944

Executives

Name Title Contact Details

Similar Companies

Formant

Robot command center that lets customers deploy faster, scale while reducing overhead, and maximize the value of a robot fleet and the data it produces.

ChooseVolta

Volta enables businesses to overcome their technology challenges. We provide Managed IT, Infrastructure, & Cybersecurity.

Quest

We are more than just a name – we are on a quest to make your information technology work harder for you. Our solutions simplify the IT operations at more than 100,000 organizations worldwide. Rely on us to help you turn data into insights quicker, modernize your infrastructure faster for the cloud, optimize the application experience and get control of every device that touches your network.

Shogun

Shogun is an ecommerce experience platform empowering brands to drive higher conversions, revenue, and brand loyalty. Our products Shogun Page Builder and Shogun Frontend help teams build and optimize their online stores to deliver exceptional experiences. Our products integrate with ecommerce platforms like Shopify and BigCommerce, and our 20,000+ customers include Leesa, MVMT, Timbuk2, and Chubbies.

Immunome

Immunome is a biotechnology company with a growing pipeline of cancer immunotherapies fueled by the human immune system. Our unique and powerful immunotherapy discovery engine leverages “most highly educated” immune systems from patients who have already learned how to fight off their disease. This proprietary technology platform enables the simultaneous discovery of novel antigens and the patient-derived, native antibodies that target those antigens. We then employ a battery of high-content screening technologies to identify specific and high-affinity antibodies that offer significant therapeutic potential to change the way we treat cancer.